Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer

Bilal A Siddiqui; Sumit K Subudhi; Padmanee Sharma

doi:10.1016/j.xcrm.2022.100613

Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer

Cell Rep Med. 2022 Apr 19;3(4):100613. doi: 10.1016/j.xcrm.2022.100613.

Authors

Bilal A Siddiqui¹, Sumit K Subudhi¹, Padmanee Sharma²

Affiliations

¹ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
² Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: padsharma@mdanderson.org.

Abstract

The addition of atezolizumab (anti-PD-L1) to enzalutamide (androgen receptor antagonist) did not prolong survival in metastatic prostate cancer.¹ Efficacy with immunotherapies in prostate cancer will require additional studies to elucidate and target mechanisms of resistance within the prostate tumor microenvironment.

Publication types

News

MeSH terms

Benzamides
Humans
Male
Nitriles
Phenylthiohydantoin* / pharmacology
Prostatic Neoplasms* / drug therapy
Tumor Microenvironment

Substances

Benzamides
Nitriles
Phenylthiohydantoin
enzalutamide

Grants and funding

T32 CA009666/CA/NCI NIH HHS/United States